BBV154 is a single-dose vaccine made using novel chimpanzee adenovirus. “Mice and hamsters immunized with a single dose of ChAd-SARS-CoV-2-S conferred superior protection against SARS-CoV-2 challenge, more so than one or two intramuscular immunizations of the same vaccine and dose. Post-challenge with SARS-CoV-2, viral clearance was observed in both lower and upper airways,” the company said on its website.
The pre-clinical testing for toxicology, immunogenicity and challenge studies were conducted in US and India. The results of the study have also been uploaded on biorxiv, a server that carries preprints of research work before it is peer reviewed.